Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
BOTHELL, WA, Feb. 03, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral...
-
BOTHELL, WA, Jan. 29, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral...
-
– Presentation on Tuesday, December 10th at 4:40 pm PST – BOTHELL, WA, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage...
-
– Following new positive data from Phase 2a study, Company outlines next steps in clinical development plan for lead program CC-31244 for ultrashort treatment of hepatitis C (HepC) – –...
-
- New data presented at the American Association for the Study of Liver Diseases (AASLD) 2019 Liver Meeting - - Patients that achieved SVR had significantly higher frequencies of terminally...
-
BOTHELL, WA, Oct. 31, 2019 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral...
-
BOTHELL, WA, Oct. 30, 2019 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral...
-
New data to be presented from U.S. Phase 2a clinical trial of CC-31244 for ultrashort treatment of hepatitis C virus (HCV)Eight of 12 patients achieved primary endpoint of sustained virologic response...
-
- Novel class of HCV antivirals targeting the NS3 helicase that can be studied for the treatment of chronic HCV infection developed utilizing Company’s unique structure-based drug design platform...
-
BOTHELL, WA, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...